Clinical trial NCT05424913: Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
Official title: Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lipodystrophy
Dunnigan Syndrome
Lead sponsor: Centre Hospitalier Universitaire de la Réunion
Sponsor class: OTHER
First posted: 2022-06-21
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation. For this the investigators want to assay the insulin resistance marker Insulin Regulated Amino Peptidase serique (IRAPs), the plasma lipidome and inflammation markers in 2 populations of insulin-resistant subjects due to Dunnigan's inherited lipodystrophy or overweight/obesity and insulin-sensitive subjects with or without a glycemic regulation disorder objectified during an Oral induced hyperglycemia. The results of the IRAPs, lipidome and inflammation assays will be compared in insulin-resistant subjects, between normoglycemic, prediabetic and diabetic subjects. Correlations will be made between these markers and the deterioration of glycemic regulation as well as with known insulin resistance parameters (HOmeostasis Assessment Model (HOMA), Quantitative Insulin-sensitivity Check Index (QUICKI),Insulin Sensitivity Index (Isi) MATSUDA).


Eligibility criteria: Inclusion Criteria:

* Subjects with Dunnigan's Lipodystrophy OR Non-lipodystrophic insulin-resistant subjects OR Insulin-sensitive non-lipodystrophic subjects
* major
* Subjects benefiting from metabolic exploration in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital.
* Subject benefiting from an oral glucose tolerance test (OGTT) during his follow-up in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital.
* Person affiliated or beneficiary of a social security scheme.
* Subject having been informed of the study in progress and having given their written consent.

Exclusion Criteria:

* Pregnant woman
* Person under guardianship or curators or deprived of liberty

Primary outcomes:
measure: Insulin Regulated Amino Peptidase sérique (IRAPs) levels
timeFrame: at inclusion
measure: inflammation markers levels
timeFrame: at inclusion
measure: lipidome markers levels
timeFrame: at inclusion
Secondary outcomes:
measure: Compare levels of Insulin Regulated Amino Peptidase sérique (IRAPs) between the 3 categories of participants
timeFrame: at inclusion
measure: Compare levels of inflammation markers between the 3 categories of participants
timeFrame: at inclusion
measure: Compare levels of lipidome markers between the 3 categories of participants
timeFrame: at inclusion
Other outcomes:
Locations:
city: Saint-Pierre
country: Réunion
facility: CHU de la Réunion
Study officials:
References: